Overview

• Phase 3 clinical trials involving over 600 participants demonstrated that gepotidacin is as effective as the standard ceftriaxone and azithromycin regimen for treating uncomplicated gonorrhoea.
• The study, published in The Lancet and presented at the ESCMID conference, confirmed the drug's efficacy against strains resistant to existing antibiotics.
• Gepotidacin, taken as a pill, provides a less invasive treatment option, potentially improving patient compliance and reducing healthcare resource demands.
• The drug, already FDA-approved for urinary tract infections, is expected to be submitted for regulatory approval for gonorrhoea treatment later this year.
• Experts caution that further research is needed to assess its effectiveness in diverse populations and to monitor the potential development of resistance over time.